These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1342585)

  • 21. Identification of large glycosylated proteins recognized by monoclonal antibodies against HIV-1 gag proteins.
    Pinter A; Honnen WJ; Revesz K; Herz R
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1341-4. PubMed ID: 1466953
    [No Abstract]   [Full Text] [Related]  

  • 22. Detection of IgG anti-HIV antibodies in mice experimentally infected with HIV-1.
    Filice G; Cereda PM; Orsolini P; Soldini L; Romero E; Rondanelli EG
    Microbiologica; 1989 Jan; 12(1):75-80. PubMed ID: 2716538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Infection with the human immunodeficiency virus, rheumatic pathology and autoimmunity].
    Nasonov EL
    Ter Arkh; 1990; 62(5):141-7. PubMed ID: 1975707
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mimicry accompanying HIV-1 infection: human monoclonal antibodies that bind to gp41 and to astrocytes.
    Eddleston M; de La Torre JC; Xu JY; Dorfman N; Notkins A; Zolla-Pazner S; Oldstone MB
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):939-44. PubMed ID: 7506553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.
    Ghetie V; Wheeler T; Scott D; Uhr JW; Vitetta ES
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1945-8. PubMed ID: 1489581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Affinity and concentration of anti-HIV antibodies in asymptomatic and symptomatic HIV infection.
    Radkowski M; Laskus T; Goch A; Slusarczyk J
    Mater Med Pol; 1991; 23(4):256-8. PubMed ID: 1842230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective immunity against HIV infection: lessons from HIV-2 infection.
    Rowland-Jones S
    Future Microbiol; 2006 Dec; 1(4):427-33. PubMed ID: 17661633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dynamic study of anti-HIV antibody avidity after cellular immunity restoration under antiretroviral treatment].
    Riou M; Renier G; Mattman S; Fialaire P; Loison J; Chennebault JM; Payan C
    Ann Biol Clin (Paris); 2000; 58(6):715-20. PubMed ID: 11098168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The specificity of enzyme immunoassays for antibodies to human immunodeficiency virus: impact on record and donor management.
    Dodd RY; Houlihan K; Lamberson HV
    Transfusion; 1993 Aug; 33(8):693. PubMed ID: 8342240
    [No Abstract]   [Full Text] [Related]  

  • 33. Reviewing the immune system.
    Nursing; 2001 Mar; 31(3):70-1. PubMed ID: 11288557
    [No Abstract]   [Full Text] [Related]  

  • 34. Autoimmune mechanisms in the pathogenesis of the acquired immunodeficiency syndrome.
    Amadori A; Chieco-Bianchi L
    Int J Clin Lab Res; 1992; 22(1):11-6. PubMed ID: 1633314
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular engineering: Antibodies, made to order.
    Eisenstein M
    Nat Methods; 2013 Oct; 10(10):930-1. PubMed ID: 24161971
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-HIV antibodies: the source of specificity.
    Vaz NM
    Braz J Med Biol Res; 1992; 25(11):1059-61. PubMed ID: 1342585
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120.
    Morrison SA; Pearson SL; Steigbigel RT
    AIDS Res Hum Retroviruses; 1998 Apr; 14(6):491-8. PubMed ID: 9566551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AIDS and Trojan horses.
    Elder D; Harris R
    Riv Biol; 1992; 85(2):247-8. PubMed ID: 1361074
    [No Abstract]   [Full Text] [Related]  

  • 39. Unusually strong, but transient, nonspecific human immunodeficiency virus types 1 and 2 antibody reactivity.
    Kiely P; Miller K; Denham-Ricks P; Kebede M
    Transfusion; 2008 Jul; 48(7):1521-2. PubMed ID: 18651910
    [No Abstract]   [Full Text] [Related]  

  • 40. Status of HIV vaccine development.
    Minor JR
    Am J Hosp Pharm; 1994 Jul; 51(14):1816-8. PubMed ID: 7942913
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.